Comparison of CD45+ Depletion Methods for Enrichment of Disseminated Tumor Cells in Bone Marrow Samples
Poster Dec 07, 2017
Birte Möhlendick, Imke Hoffmann, Swetlana Seidschner, Sarah Schumacher, Alexander Smyczek, Carina Vaerst, Wolfram Trudo Knoefel, Nikolas Hendrik Stoecklein
Disseminated tumor cells (DTC) in bone marrow (BM) samples are, with a frequency of only one DTC per 1x106 cells, quite rare. DTCs are usually detected utilizing immunofluorescence staining of 1-2x106 mononuclear cells (MNC) and consecutive microscopic analysis. To increase the detection rate of DTCs a higher number of cells should be analyzed. Since microscopic detection of these cells is very laborious DTC enrichment strategies are needed. Here, we investigated the efficiency of three different depletion strategies of CD45+ cells for DTC enrichment in BM samples.
CD45+ cell depletion was performed on BM samples from cancer patients with different tumor entities. Immunomagnetic depletion (DYN) of CD45+ cells was performed after Ficoll density gradient centrifugation on 1x107 MNCs utilizing CD45 Dynabeads® (Invitrogen) with i) 4x107 beads/ml cell suspension (DYNLO) and ii) 1x108 beads/ml cells suspension (DYNHI). Antibody-based depletion (ROS) of CD45+/CD66b+ cells was performed on 1x108 BM cells with the RosetteSep® Human CD45 Depletion Cocktail (Stemcell Technologies). For the different strategies at least 60 samples were analyzed, the depletion efficiency was calculated and DTC numbers were extrapolated to compare the respective methods.
We were able to detect DTCs in 32.7% (DYNLO), 12.5% (DYNHI) and 66% (ROS) of the patient samples, respectively. CD45+ cells could be depleted most efficiently up to 440-fold using ROS, followed by 44-fold with DYNHI and 20-fold using DYNLO. DTC numbers were significantly higher (p<0.0001) in the ROS samples (mean=3.69) with up to 21 DTCs per 1x106 cells. With the immunomagnetic procedures DYNLO samples (mean=0.48) had slightly higher DTC counts (8.33 vs 6.35 DTCs per 1x106 cells) compared to DYNHI (mean=0.39).
In our hand the ROS procedure showed the best results for DTC enrichment from BM samples. This method enables the analysis of a high number of BM cells since it depletes unwanted CD45+ cells most efficiently and thus increases DTC detection rates in the patient samples.
Characterization of a Type 2 diabetes-associated islet-specific enhancer cluster in STARD10 by genome editing of EndoC-βH1 cellsPoster
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
P450 Induction in Cryopreserved Hepatocytes from PXR and CAR Nuclear Receptor Knock-out RatsPoster
The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of phase I (cytochrome P450s), phase II metabolizing enzymes and transporter genes in response to xenobiotics, including prescription drugs.READ MORE
Mass Spectrometry: From Imaging to Metabolic NetworksPoster
We show that network analysis of co-localized ions from mass spectrometry imaging data provides a detailed chemo-spatial insight into the metabolic heterogeneity of tumors. Furthermore, module preservation analysis between colorectal cancer patients with and without metastatic recurrence suggests hypotheses on the nature of the different local metabolic pathways.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018